L&C BIO Co., Ltd Logo

L&C BIO Co., Ltd

Develops tissue grafts, medical devices, and cosmetics for tissue regeneration medicine.

290650 | KO

Overview

Corporate Details

ISIN(s):
KR7290650001
LEI:
Country:
South Korea
Address:
경기도 성남시 중원구 둔촌대로 474, 605호, 606호, 607호 (선텍시티), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

L&C BIO Co., Ltd. is a biotechnology company specializing in tissue regeneration medicine. The company develops and manufactures human tissue grafts, allograft-based medical devices, and cosmetics. It is a leader in the South Korean skin graft market and operates one of Asia's largest skin and soft tissue banks, utilizing patented processing technologies. Committed to continuous research and development, L&C BIO aims to improve global health and quality of life by becoming a leading global bio-health company.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-08-26 00:00
Transaction in Own Shares
자기주식취득결과보고서
Korean 35.7 KB
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 1.7 MB
2025-07-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 73.0 KB
2025-07-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 79.5 KB
2025-06-30 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 143.2 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-06-23 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득결정)
Korean 32.8 KB
2025-06-16 00:00
Capital/Financing Update
[기재정정]교환사채권발행결정(종속회사의주요경영사항)
Korean 36.9 KB
2025-06-12 00:00
Capital/Financing Update
교환사채권발행결정(종속회사의주요경영사항)
Korean 32.6 KB
2025-06-12 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 79.9 KB
2025-06-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 75.3 KB
2025-05-27 00:00
Share Issue/Capital Change
[기재정정]전환청구권행사
Korean 12.7 KB
2025-05-27 00:00
Share Issue/Capital Change
전환청구권행사
Korean 10.0 KB
2025-05-26 00:00
Share Issue/Capital Change
주요사항보고서(제3자의전환사채매수선택권행사)
Korean 16.3 KB

Automate Your Workflow. Get a real-time feed of all L&C BIO Co., Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for L&C BIO Co., Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for L&C BIO Co., Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP
ARROWHEAD PHARMACEUTICALS, INC. Logo
Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.
United States of America
ARWR
ARS Pharmaceuticals, Inc. Logo
Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.
United States of America
SPRY

Talk to a Data Expert

Have a question? We'll get back to you promptly.